Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Go Watanabe

1PUBLICATIONS
24CO-AUTHORS
Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (1)

Sort by Publication Date:
|May 19, 2023
Tumor-derived semaphorin 4A improves PD-1-blocking antibody efficacy by enhancing CD8<sup>+</sup> T cell cytotoxicity and proliferation.

Yujiro Naito, Shohei Koyama, Kentaro Masuhiro

Pageof 1

Frequent Collaborators

1 joint publications

Yujiro Naito

1 joint publications

Shohei Koyama

1 joint publications

Kentaro Masuhiro

1 joint publications

Nicolas Sax

1 joint publications

Jordan Villa

1 joint publications

Satoshi Nojima

1 joint publications

Moto Yaga

1 joint publications

Daisuke Okuzaki

1 joint publications

Shingo Satoh

1 joint publications

Takeshi Tsuda

Frequent Collaborators

1 joint publications

Yujiro Naito

1 joint publications

Shohei Koyama

1 joint publications

Kentaro Masuhiro

1 joint publications

Nicolas Sax

Top Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8<sup>+</sup> T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8<sup>+</sup> T Cell Responses

Published on : May 06, 2019

9.0K
See more related videos

Top Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8<sup>+</sup> T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8<sup>+</sup> T Cell Responses

Published on : May 06, 2019

9.0K
See more related videos